Spirapril Hydrochloride

CHEMBL1200831 Phase 4 승인됨 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
503.1 g/mol
LogP
Phase
4

Spirapril hydrochloride is the hydrochloride salt form of spirapril, an ACE inhibitor prodrug used for hypertension and cardiovascular disease prevention. See spirapril for complete pharmacological details.

분자량

503.1000 g/mol

TPSA

147.00 Ų

치료 영역

작용 기전

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

2D 구조

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2.Cl

InChI

InChI=1S/C22H30N2O5S2.ClH/c1-3-29-21(28)17(10-9-16-7-5-4-6-8-16)23-15(2)19(25)24-14-22(30-11-12-31-22)13-18(24)20(26)27;/h4-8,15,17-18,23H,3,9-14H2,1-2H3,(H,26,27);1H/t15-,17-,18-;/m0./s1

Molecular Formula

C22H31ClN2O5S2

HBD / HBA

3 / 8

회전 가능 결합

10

무거운 원자

32

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

Spirapril hydrochloride is the hydrochloride salt form of spirapril, an ACE inhibitor prodrug used for hypertension and cardiovascular disease prevention. See spirapril for complete pharmacological details.

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Yes, Spirapril Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200831. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6850814. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.